Released on: October 28, 2008, 3:46 pm

Press Release Author: The Scott Partnership

Industry: Biotech

Press Release Summary: (October 28, 2008) Biotage, a leading supplier of tools and
technology for medicinal and analytical chemistry, announces the release of its new
2008-09 Synthesis and Purification Catalog. The new 336-page catalog includes a
range of products for microwave synthesis, work-up, flash purification and
evaporation. To order a catalog, please visit www.biotage.com

Press Release Body:
News release
Contact:
Jennifer Whedbee, Director Marketing Communications
Tel: +1 434 220 2652, jwhedbee@biotage.com


Biotage Introduces a New Synthesis and Purification Catalog

(October 28, 2008) Biotage, a leading supplier of tools and technology for medicinal
and analytical chemistry, announces the release of its new 2008-09 Synthesis and
Purification Catalog. The new 336-page catalog includes a range of products for
microwave synthesis, work-up, flash purification and evaporation. To order a
catalog, please visit www.biotage.com.

This new Biotage catalog offers valuable information on applications along with
comprehensive information to assist with system and consumable selection. A list of
published microwave reactions provides quick reference to papers illustrating the
wide-ranging benefits of microwave synthesis. The catalog also contains strategies
for using solid-bound reagents to achieve higher purities, work-up solutions and
scavenger selection guides.

New featured products include: the latest Biotage flash purification system,
Isolera(tm) along with SNAP(tm) flash cartridges and the innovative V10 solvent
evaporation system which quickly and safely dries dissolved compounds. Also Biotage
has included the consumable and spare-part pricing for quick and easy reference when
ordering.

The new Isolera(tm) FLASH purification system and new full range SNAP cartridge line,
were both launched in 2008. These state-of-the-art flash chromatography tools enable
chemists to easily achieve better separations in significantly shorter purification
run-times.

For more information on the Biotage range of synthesis and purification products,
please email product_info@biotage.com or visit www.biotage.com to order a catalog.


-ENDS-
For further press information please contact: Eleanor CallanMonk, The Scott
Partnership, 1 Whiteside, Station Road, Holmes Chapel, Cheshire CW4 8AA Tel: +44
1477 539539 Fax: +44 1477 539540 e-mail: biotage@scottpr.com

About Biotage
Biotage is a global company active in life science research with strong
technologies, a broad range of operations and a long-term view of the market. The
company offers solutions, knowledge and experience in the areas of genetic analysis
and medicinal chemistry. In 2005 operations and products were acquired from the
American company Argonaut, further strengthening the medicinal chemistry product
range. The customers include the worlds top 30 pharmaceutical companies, the worlds
top 20 biotech companies, and leading academic institutes. The company is
headquartered in Uppsala and has offices in the U.S., Japan, UK, Germany and several
other European countries. Biotage has 336 employees and had sales of 496,4 MSEK in
2007. Biotage is listed on the OMX Nordic Exchange Stockholm AB. Website:
www.biotage.com

Certain statements in this press release are forward-looking. These may be
identified by the use of forward-looking words or phrases such as "believe,"
"expect," "intend," and "should," among others. These forward-looking statements are
based on Biotage's current expectations. The Private Securities Litigation Reform
Act of 1995 provides a "safe harbor" for such forward-looking statements. In order
to comply with the terms of the safe harbor, Biotage notes that a variety of factors
could cause actual results and experience to differ materially from the anticipated
results or other expectations expressed in such forward-looking statements. Such
uncertainties and risks include, but are not limited to, risks associated with
management of growth and international operations (including the effects of currency
fluctuations), variability of operating results, the commercial development of the
microwave synthesis and flash purification in the drug discovery market, DNA
sequencing and genomics market, nucleic acid-based molecular diagnostics market, and
genetic vaccination and gene therapy markets, competition, rapid or unexpected
changes in technologies, fluctuations in demand for Biotage's products (including
seasonal fluctuations), difficulties in successfully adapting the Company's products
to integrated solutions and producing such products, and the Company's ability to
identify and develop new products and to differentiate its products from
competitors.


Web Site: http://

Contact Details: Jennifer Whedbee, Director Marketing Communications
Tel: +1 434 220 2652, jwhedbee@biotage.com